• Company Vision
• Businesses
• Global Presence
• Partnerships
• Executive Committee
• Corporate Responsibility
• Company History
• Therapeutic Areas
• Investor Information

_The iron franchise focuses its activities on iron deficiency with or without anaemia, a globally widespread ailment. Key brands in the iron replacement product portfolio of Vifor Pharma are Ferinject^®, Venofer^® and Maltofer^®. The intravenous and oral iron replacement therapies serve the following therapeutic areas: haemodialysis, non-dialysis chronic kidney diseases (ND-CKD), cardiology, oncology, obstetrics and gynaecology, gastroenterology, patient blood management, women’s health and paediatrics. To provide scientific evidence for the efficiency and safety of intravenous iron therapy in these patients, Vifor Pharma has a comprehensive clinical and scientific development programme in place.
_For more information visit the iron therapies section

_Vifor Fresenius Medical Care Renal Pharma Ltd. is a strategic partnership between Vifor Pharma and Fresenius Medical Care.
_To strengthen its position in the global intravenous iron market Vifor Pharma first joined forces with Fresenius Medical Care, the world leader in dialysis products and services in 2008 with exclusive licence agreements for the commercialisation of Venofer^® and Ferinject^® for iron deficiency anaemia in haemodialysis in the USA, Europe, the Middle East, Africa and Latin America.
_In December 2010 Vifor Pharma and Fresenius Medical Care announced an extension of their partnership through the creation of a specialty pharmaceuticals company, Vifor Fresenius Medical Care Renal Pharma Ltd. The new nephrology company develop and commercialise innovative and high-quality products to improve the lives of patients suffering from chronic kidney disease worldwide.
_The products of the new company include Venofer^® and Ferinject^® (Injectafer^®, the brand name for Ferinject^® in the USA, the product is currently in the approval process) in the field of dialysis and pre-dialysis (CKD stage III – V) as well as PA21, a novel iron-based phosphate binder.

_The Infectious Diseases / OTX product portfolio is made up of about 10 products and includes products for brain function and development, ear care, abdominal distension, chronic obstructive pulmonary disease, respiratory tract Infections, lower urinary tract infections, chronic venous insufficiency, diabetic retinopathy, haemorrhoids, menometrorrhagia or heavy menstrual bleeding.
_The key brands are Equazen^TM, Otalgan^®, Aero-OM^®, Broncho-Vaxom^®, Uro-Vaxom^®, Doxium^® and Dicynone^®.
_Vifor Pharma continues to internationalise the product range. The majority of sales come from approximately 100 countries in Europe, Asia, Africa, Latin America and the Middle East.
_Visit the Infectious Diseases / OTX products section 

_The franchise Consumer Healthcare manufactures and markets non-prescription drugs (over-the-counter products) developed by Vifor Pharma or sold under licence. Vifor Pharma plays a leading role in its home market Switzerland with key brands such as Algifor^®, Triofan^®, Perskindol^® or Anti-Brumm^®.
_For more information visit the Consumer Healthcare Switzerland website.

_The development and production of products for third parties, contract development and contract manufacturing, is another pillar of Vifor Pharma’s business. We use our diversified manufacturing equipment for the production of solid, semi-solid and liquid forms.
_For more information click here.

Links

• Home
• About Vifor Pharma
• Businesses